Public Forum
Default group for all members. Biological family sometimes get you down? Come join your logical family!
Organizers:
- Organized by
-
-
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
-
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID<div>
Dr. Soon-Shiong is taking a very interesting approach, and if you’re in the San Francisco area, this would be an interesting one to participate in:
“We are excited to study ANKTIVA for the treatment of long COVID, a substantial public health concern,” said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. “Early in the pandemic, the common assumption was SARS-CoV-2 would prove to be a transient infection, as is the case with coronaviruses in general. But we now know viral nucleic acid and proteins can be in the gut mucosa months after infection. As such, an antiviral strategy looks insufficient to treat or cure long COVID. Based on clinical insights to date, we believe ANKTIVA may be a new therapeutic option for this chronic and potentially disabling condition by enhancing immune function, facilitating viral clearance, and addressing underlying contributions to long COVID.“
The study, which is being conducted by ImmunityBio and aims to recruit up to 40 participants who meet the long COVID criteria, as established by the World Health Organization (WHO), is now accepting patients for initial screening to determine study eligibility. The safety and tolerability of ANKTIVA for long COVID is also being assessed in a separate Phase 2 study conducted at the University of California – San Francisco. Both studies are supported by ImmunityBio. To learn more, visit https://immunitybio.com/find-a-trial/.
</div>
finance.yahoo.com
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
CULVER CITY, Calif., August 19, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), in patients with long COVID. An … Continue reading
-
2 Replies
-
I should add, another reason why this is groundbreaking is because Dr. Soon-Shiong has had this science in the works for many years now, however, he has pointed out that Francis Collins (Francis Collins – Wikipedia) and other deep state actors have been at odds with him and his approaches to cancer and COVID. Sec. Kennedy met with Dr. Soon-Shiong and stated he would support him.
It’s not hard to figure out this statement from the Francis Collins wikipedia article:
After he step down as the director of NIH in December 2021, Collins returned to his 12-person research lab at NHGRI. Except for an eight-month stint as the acting presidential science advisor, Collins performed full-time biomedical research[82][83] until he announced his retirement on February 28, 2025.[84] Collins did not give a reason for his abrupt departure.[85]
I’m a big fan of this turn of events in the name of MAHA and watching with excitement to see how these trials go.
-
👍 I hope the reasons become clear, and hopefully accountable too.
-
Log in to reply.